BillionToOne, Inc. Class A Common Stock (BLLN)vsDanaher Corporation (DHR)
BLLN
BillionToOne, Inc. Class A Common Stock
$74.08
-6.92%
HEALTHCARE · Cap: $3.49B
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 7952% more annual revenue ($24.57B vs $305.11M). DHR leads profitability with a 14.7% profit margin vs 1.0%. DHR trades at a lower P/E of 37.7x. DHR earns a higher WallStSmart Score of 60/100 (C).
BLLN
Avoid34
out of 100
Grade: F
DHR
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-8925.3%
Fair Value
$0.95
Current Price
$74.08
$73.13 premium
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 113.1% year-over-year
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of 2.3% — below average capital efficiency
1.0% margin — thin
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth. Revenue growth of 113.1% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bear Case : BLLN
The primary concerns for BLLN are EPS Growth, Return on Equity, Profit Margin. A P/E of 542.9x leaves little room for execution misses. Thin 1.0% margins leave little buffer for downturns.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.
BLLN is growing revenue faster at 113.1% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (60/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?